This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
PE funds typically have 4-to-7-years ownership windows for an investment and look for an exit at the end of that period through a sale or an IPO (initialpublicoffering). Peaked market valuations: When market cycle peaks or an industry fully matures, it may be advantageous for shareholders to cash out.
Invest in strategic initiatives to boost your company’s performance and market position, ultimately increasing its valuation. A diversified revenue portfolio strengthens your business’s resilience and makes it more attractive to a broader range of buyers.
Strategic innovation Strategic acquirers are feeling more pressure to consummate bolt-on acquisitions in order to round out their portfolios, enter new markets and fill innovation gaps. Moving into Q2 of 2023, roughly 29% of US public biotech companies traded below their cash value.
Amid depressed valuations, biotechnology companies also saw an increasing number of demands from activist investors that in certain cases led to more deal activity. Of course, we continue to see many parties discussing licensing deals deciding to do just that – turning to a full acquisition after initial licensing discussions.
However, deal activity fizzled in the second half of 2022, as high inflation, aggressive anti-inflation monetary policies, geopolitical instability, assertive antitrust regulators and tightening financing markets depressed target valuations, reduced strategic acquirer confidence and sidelined private equity sponsor buyers. trillion. [2]
.* *FOCUS research I suspect we would have already seen several of these exits were it not for various factors including high valuation targets relative to market demand. Public Markets: It is possible that a few of the car wash platforms with strong growth and financial performance pursue an initialpublicoffering (IPO).
Portfolio optimization through divestitures of noncore assets In addition to pharmas smaller appetite in 2024, pharma companies continued to slim down by shedding nonessential assets to sharpen their strategic focus on core products.
We organize all of the trending information in your field so you don't have to. Join 38,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content